Researching Modifiable and Non-Modifiable Risk Factors Linked to Cognitive Resilience in Alzheimer’s Disease
What do we do?
Our lab focuses on clarifying how alterations in the brain and other biomolecules (such as cerebrospinal fluid β-amyloid) place some cognitively-normal individuals on a pernicious trajectory that culminates in Alzheimer’s dementia. In this context, we are also interested in discovering new knowledge concerning the modulation of the link between brain changes and cognitive decline by both modifiable (e.g., cognitively-stimulating activities, physical exercise) and non-modifiable (e.g., genetic vulnerability) factors.
We use many techniques in our research, including but not limited to:
This is an accordion element with a series of buttons that open and close related content panels.
MRI and PET Imaging
Cerebrospinal Fluid Collection
Maximal Exercise Testing
Physical Activity Monitoring
We are a part of the larger Wisconsin Alzheimer’s Disease Research Program, which includes both the Wisconsin Alzheimer’s Disease Research Center and the Wisconsin Alzheimer’s Institute.
Our offices are located on UW Madison’s campus within the UW Hospital. The majority of our research is conducted within the UW Hospital, the Waisman Center, the Wisconsin Institute for Medical Research, and the YMCA.
Ira Frahmand has been invited to give an oral presentation at the AD/PD 2023 International Conference for her abstract “Alzheimer’s disease biomarker status is associated with KLOTHO genotype but not klotho protein levels in an …December 1, 2022
Ozioma has been invited to serve on the NIA-Alzheimer’s Association expert workgroup that establishes definitions and boundary classifications for Alzheimer’s disease (i.e., the NIA-Alzheimer’s Association Research Framework for Alzheimer’s Disease).December 1, 2022
Noah Cook’s abstract “Alzheimer’s disease biomarker status associates with KLOTHO genotype but not klotho protein levels in an at-risk cohort” was accepted for a poster presentation at the 2022 Department of Medicine Research Day. This …December 1, 2022
Ira Frahmand’s manuscript “AD-associated CSF biomolecular changes are attenuated in KL-VS heterozygotes” was accepted for publication in Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring. Congratulations, Ira!December 1, 2022
- More News